ISTA Pharmaceuticals, Inc. pled guilty to conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. The guilty pleas were part of a global settlement with the United States in which ISTA agreed to pay 33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.